Seminars in Oncology Nursing
Volume 23 , Pages S3-S10 , November 2007

Bladder Cancer: Epidemiology, Diagnosis, and Treatment

  • Patricia Creel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Patricia Creel, RN, BSN, OCN®, CCRP, Duke University Medical Center, Department of Surgery, Division of Urology, 330 Baker House, Trent Drive, Durham, NC 27710

References 

  1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society. Available at: www.cancer.org (accessed November 2, 2007).
  2. American Cancer Society: What are the risk factors for bladder cancer? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_2X_What_are_the_risk_factors_for_bladder_cancer_44.asp (accessed September 2, 2007).
  3. US National Institute of Health, National Cancer Institute (n.d.). Bladder Cancer PDQ. Available at: www.cancer.gov/cancertopics/types/bladder (accessed May 22, 2007).
  4. National Comprehensive Cancer Network (2007). NCCN Practice Guidelines in Oncology – v.1.2007. Available at: http://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf (accessed May 19, 2007).
  5. Ries LAG, Melbert D, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2004/. Based on November 2006 SEER data submission, posted to the SEER web site, 2007 (accessed September 2, 2007).
  6. Steinberg GD. Bladder Cancer. Available at: http://www.emedicine.com/MED/topic2344.htm (accessed May 20, 2007).
  7. Dalquen P, Kleiber B, Grilli B, et al. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer. 2002;96:374–379
  8. Fredrich MG, Pichimeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123–1130
  9. Chung P, Gospodarowicz M, Warde P, et al. Long-term effects of conservation therapy for muscle invasive bladder carcinoma. [abstract 4519] Proc Am Soc Clin Oncol. 2004;22:385
  10. Barjorin DF, Bochner BH, Sandler HM, et al. Changing paradigms in advanced bladder cancer. American Society of Clinical Oncology 2005 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2005;pp 330-350
  11. Fitzpatrick JM, West AB, Butler MR, et al. Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection. J Urol. 1986;135:920–922
  12. Heney NM, Nocks BN, Daly JJ, et al. Ta and T1 bladder cancer: Location, recurrence and progression. Br J Urol. 1982;54:152–157
  13. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083–1086
  14. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study. J Clin Oncol. 1993;1:2150–2157
  15. Sauer R, Birkenhake S, Kuhn R, et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys. 1998;30:121–127
  16. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60:62–68
  17. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy and Oncology Group 89-03. J Clin Oncol. 1998;16:3576–3583
  18. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: Future alternatives to radical cystectomy. Annals Med. 2000;32:34–42
  19. Schrag D, Hsieh LJ, Rabbani F, et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95:588–597
  20. Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol. 1997;158:393–399
  21. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multicenter study. J Urol. 2004;171:139–144
  22. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–675
  23. Mills RD, Turner WH, Fleischmann A, et al. Pelvic lymph node metastases from bladder cancer: Outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol. 2001;166:19–23
  24. Bassi P, Pagano F, Pappagallo G. Neoadjuvant M-VAC of invasive bladder cancer: GUONE multicenter phase III trial. [abstract 567] Eur Urol. 1998;33:142
  25. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001;165:811–814
  26. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol. 1995;153:964–973
  27. Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol. 1992;147:606–608
  28. Wallace DM, Raghavan D, Kelly KA, et al. Neoadjuvant (preemptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67:608–615
  29. Waehre H, Ous S, Klevmak B, et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer. 1993;72:3044–3051
  30. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005–4013
  31. Natale RB. Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer. Curr Oncol Rep. 2000;2:386–393
  32. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant Chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866[erratum appears in N Engl J Med 2003;349:1880]
  33. Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999;17:2546–2552
  34. Miller RS, Freiha FS, Reese JH, et al. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol. 1993;150:65–69
  35. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M.D. Anderson experience. J Urol. 2004;171:145–148
  36. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Review and meta-analysis. Lancet. 2003;361:1927–1934
  37. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:202–206
  38. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608
  39. Galsky MD, Scher HI. Bladder cancer “adjuvant-lite”: Tastes great (works as well) and less filling (less toxic)?. J Clin Oncol. 2005;23:4823–4826
  40. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48:189–201

PII: S0749-2081(07)00094-0

doi: 10.1016/j.soncn.2007.10.007

Seminars in Oncology Nursing
Volume 23 , Pages S3-S10 , November 2007

Article Tools

* Image Usage & Resolution